Biotech Director Gets Major Equity Stake: Arvinas Grants 39K Shares to Board Member

Rhea-AI Filing Summary

Arvinas Director Receives Equity Compensation Package

Director Laurie Smaldone Alsup received significant equity awards from Arvinas (NASDAQ: ARVN) on June 25, 2025. The compensation package includes:

• 16,025 Restricted Stock Units (RSUs) with zero acquisition cost
• 23,105 Stock Options with an exercise price of $7.80 per share and expiration date of June 24, 2035

Both equity awards will vest in full on the earlier of June 25, 2026 or the first board meeting following the next annual stockholder meeting, contingent on continued service. Following these transactions, Smaldone Alsup directly owns 26,045 shares of common stock and 23,105 stock options. This grant appears to be part of the company's regular director compensation program.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Smaldone Alsup Laurie

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	23,105	$0.00	--
Grant/Award	Common Stock	16,025	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 23,105 shares (Direct); Common Stock — 26,045 shares (Direct)

Footnotes (1)

1. The restricted stock units (each, an "RSU") were granted by the Issuer on June 25, 2025 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date. This option award was granted on June 25, 2025. The shares underlying the award shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smaldone Alsup Laurie

(Last) (First) (Middle)

C/O ARVINAS, INC.

5 SCIENCE PARK, 395 WINCHESTER AVE.

(Street)

NEW HAVEN CT 06511

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARVINAS, INC. [ ARVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2025		A		16,025(1)	A	$0	26,045	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.8	06/25/2025		A		23,105		(2)	06/24/2035	Common Stock	23,105	$0	23,105	D

Explanation of Responses:

1. The restricted stock units (each, an "RSU") were granted by the Issuer on June 25, 2025 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date.

2. This option award was granted on June 25, 2025. The shares underlying the award shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date.

Remarks:

	/s/ Jared Freedberg, as attorney-in-fact for Laurie Smaldone Alsup	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ARVN stock options did Laurie Smaldone Alsup receive on June 25, 2025?

Laurie Smaldone Alsup received 23,105 stock options with an exercise price of $7.80 per share on June 25, 2025. These options will vest in full on the earlier of June 25, 2026 or the first board meeting after the next annual stockholders meeting.

How many restricted stock units (RSUs) were granted to ARVN's director Laurie Smaldone Alsup?

Laurie Smaldone Alsup was granted 16,025 restricted stock units (RSUs) on June 25, 2025. Each RSU represents a right to receive one share of Arvinas common stock at no cost upon settlement.

When do Laurie Smaldone Alsup's ARVN stock options and RSUs vest?

Both the stock options and RSUs will vest in full on the earlier of either June 25, 2026 or the first meeting of the board of directors held after the next annual meeting of stockholders, subject to continued service with Arvinas.

What is the total number of ARVN shares beneficially owned by Laurie Smaldone Alsup after the June 25, 2025 grants?

Following the reported transactions, Laurie Smaldone Alsup directly owns 26,045 shares of Arvinas common stock, plus 23,105 stock options and 16,025 unvested RSUs.

What is the expiration date of ARVN stock options granted to Laurie Smaldone Alsup?

The stock options granted to Laurie Smaldone Alsup on June 25, 2025 have an expiration date of June 24, 2035, giving them a 10-year term.